Document is current
Any future updates will be listed below
-
Authors
Neyra, Adrián
Parro-Torres, Carlos
Ros-Cucurull, Elena
Carrera, Indalecio
Echarri, Eduardo
Torrens, Marta
-
Funding
Funding for this research was provided by:
Otsuka Pharmaceutical S.A.
Lundbeck España S.A.
- License Information
-
More Information
Article History
Received: 30 July 2024
Accepted: 20 October 2024
First Online: 30 October 2024
Declarations
:
: Not applicable.
: Not applicable.
: AN has been a consultant and/or speaker and/or has received research grants from Angelini Pharma S.L.U.; Lundbeck, Inc.; Janssen Pharmaceuticals, Inc.; Laboratorios Farmacéuticos ROVI SA.; Otsuka Pharmaceutical Co.; Pfizer Inc.; AstraZeneca Pharmaceuticals LP.; and Esteve Pharmaceuticals, S.A. CPT has been a consultant or has received fees for collaborations from Lundbeck, Janssen, MSD, Esteve, and Casen Recordati. ERC has received financial compensation for her participation as a speaker and/or board member from Angelini, Casen Recordati, Esteve, Exeltis, Idorsia, Janssen, Juste, Lilly, Lundbeck, Otsuka, Pfizer, Rovi, Servier. She has received research grants from Acadia, Boehringer Ingelheim, Eisai, HMNC Holding GmbH, Janssen, Lundbeck, Novartis, Otsuka, Roche. MT has been a consultant or has received fees for collaborations from Lundbeck, Otzuca, MSD, Camurus, Rovi, Servier, Adamet, Angellini. IC and EE declare no conflicts of interest.
